
FDA Grants Priority Review to Orca Bio’s BLA for Orca-T® in Blood Cancers
Orca Bio’s Orca-T Receives FDA Priority Review for Treatment of Blood Cancers, Marking Major Step Toward Potential First-in-Class Therapy Orca Bio, a late-stage biotechnology company pioneering high-precision cell therapies to transform outcomes for patients with hematologic malignancies, has announced a…












